Global mRNA Treatment Market

mRNA Treatment Comprehensive Study by Type (Individualized Cancer Treatment, Infection Prevention, Standardization of Cancer Treatment, Infectious Disease Treatment), Application (Infectious Disease, Cancer, Tumors, Respiratory Diseases, Other), End Use (Hospitals, Specialty Clinics, Surgical Centers) Players and Region - Global Market Outlook to 2026

mRNA Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is mRNA Treatment?
mRNA vaccines market has followed a fast pace growth due to global epidemic of SARS Covid-19; mRNA-based treatments have emerged as a safe and potent approach for the induction of cellular immune response. The Superiority of mRNA in treating serious diseases including is highlighted as DNA and Viral Vector based treatment methods have serious health implications besides from acting as a cure. mRNA vaccines are proven most effective against Cancer, Infections, and Respiratory diseases. Recent developments have led to advanced mRNA vaccines that enable its applicational use. Although preclinical studies have shown that mRNA vaccines can induce antitumor immunity, there are several roadblocks to their widespread use. Many regions are now highly invested in R&D to mitigate the limitations associated to mRNA treatments, this derives a market growth opportunity in the coming years and the post-Covid situation.

The market study is broken down by Type (Individualized Cancer Treatment, Infection Prevention, Standardization of Cancer Treatment and Infectious Disease Treatment), by Application (Infectious Disease, Cancer, Tumors, Respiratory Diseases and Other) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth Analysts at AMA Research estimates that Players from United States and German will contribute to the maximum growth of Global mRNA Treatment market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Serum Institute (India), Pfizer (United States), GlaxoSmithKline PLC (United Kingdom), Arcturus Therapeutics Inc. (United States), Ethris GmbH (Germany), Moderna Therapeutics Inc. (United States), Translate Bio Inc. (United States), BioNTech SE (Germany), CureVac AG (Germany) and Argos Therapeutics Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Etherna (Belgium), Sangamo Therapeutics Inc. (United States) and Merck & Co. (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global mRNA Treatment market by Type, Application and Region.

On the basis of geography, the market of mRNA Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Use, the sub-segment i.e. Hospitals will boost the mRNA Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 9th April, 2020 – Pfizer along with BioNTech Announce Joint Collaboration to Develop Coid-29 Vaccine. The Collaboration Combines BioNTech’s Proprietary BNT162b2 mRNA Vaccine Platforms with Pfizers Strong Research & Development, Regulatory Capabilities Together and On 7th January, 2021 - Merck & Co Completed Its Acquisition of AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics. This Acquisition Adds to Merck's Lipid Manufacturing Expertise, Providing an Integrated Offering Across mRNA Value Chain Globally
On 24th November, 2020 – Sreum Institute launches its First mRNA Based Covid-19 Vaccine named “Covishield” and On 11th March, 2021 – Moderna Begins Phase 2 of its Booster Covid-19 Vaccine Trials, The Phase 2 Trial Amendment Has Enrolled 60 Participants Who Have Already Received Moderna’s Original mRNA-1273 Vaccine
United States, Food and Drug Administration “vaccines and Related Biological Products Advisory Committee” mRNA-1273; Provides a Comprehensive List of Procedures Regarding the Usage and Dosage Requirements for mRNA Based Vaccines Across US and European Union, Regulation 536/2014; Relates to Clinical Trials of All the Vaccines and Treatments Based on mRNA Across European Union. Any New Treatment or Vaccine is Required to have a Regulatory Approval from the European Commission

Market Trend
  • Technical Progress in Medical Industry
  • Heavy Investments in Research & Development

Market Drivers
  • Prevalence of Cancer & Severe Acute Respiratory Syndrome (SARS) Cases
  • Emergence of Advance and Effective Techniques
  • Safe and Superior to Plasmid DNA or Viral Vector Treatment

Opportunities
  • Growth in Healthcare infrastructure Due to Pandemic
  • Regulations in Promoting use of mRNA in Treatment

Restraints
  • Instability Concerns

Challenges
  • Low Immunogenicity


Key Target Audience
Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Individualized Cancer Treatment
  • Infection Prevention
  • Standardization of Cancer Treatment
  • Infectious Disease Treatment
By Application
  • Infectious Disease
  • Cancer
  • Tumors
  • Respiratory Diseases
  • Other
By End Use
  • Hospitals
  • Specialty Clinics
  • Surgical Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Cancer & Severe Acute Respiratory Syndrome (SARS) Cases
      • 3.2.2. Emergence of Advance and Effective Techniques
      • 3.2.3. Safe and Superior to Plasmid DNA or Viral Vector Treatment
    • 3.3. Market Challenges
      • 3.3.1. Low Immunogenicity
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
      • 3.4.2. Heavy Investments in Research & Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global mRNA Treatment, by Type, Application, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global mRNA Treatment (Value)
      • 5.2.1. Global mRNA Treatment by: Type (Value)
        • 5.2.1.1. Individualized Cancer Treatment
        • 5.2.1.2. Infection Prevention
        • 5.2.1.3. Standardization of Cancer Treatment
        • 5.2.1.4. Infectious Disease Treatment
      • 5.2.2. Global mRNA Treatment by: Application (Value)
        • 5.2.2.1. Infectious Disease
        • 5.2.2.2. Cancer
        • 5.2.2.3. Tumors
        • 5.2.2.4. Respiratory Diseases
        • 5.2.2.5. Other
      • 5.2.3. Global mRNA Treatment by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
        • 5.2.3.3. Surgical Centers
      • 5.2.4. Global mRNA Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. mRNA Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Serum Institute (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Arcturus Therapeutics Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ethris GmbH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Moderna Therapeutics Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Translate Bio Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BioNTech SE (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CureVac AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Argos Therapeutics Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global mRNA Treatment Sale, by Type, Application, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global mRNA Treatment (Value)
      • 7.2.1. Global mRNA Treatment by: Type (Value)
        • 7.2.1.1. Individualized Cancer Treatment
        • 7.2.1.2. Infection Prevention
        • 7.2.1.3. Standardization of Cancer Treatment
        • 7.2.1.4. Infectious Disease Treatment
      • 7.2.2. Global mRNA Treatment by: Application (Value)
        • 7.2.2.1. Infectious Disease
        • 7.2.2.2. Cancer
        • 7.2.2.3. Tumors
        • 7.2.2.4. Respiratory Diseases
        • 7.2.2.5. Other
      • 7.2.3. Global mRNA Treatment by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
        • 7.2.3.3. Surgical Centers
      • 7.2.4. Global mRNA Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. mRNA Treatment: by Type(USD Million)
  • Table 2. mRNA Treatment Individualized Cancer Treatment , by Region USD Million (2015-2020)
  • Table 3. mRNA Treatment Infection Prevention , by Region USD Million (2015-2020)
  • Table 4. mRNA Treatment Standardization of Cancer Treatment , by Region USD Million (2015-2020)
  • Table 5. mRNA Treatment Infectious Disease Treatment , by Region USD Million (2015-2020)
  • Table 6. mRNA Treatment: by Application(USD Million)
  • Table 7. mRNA Treatment Infectious Disease , by Region USD Million (2015-2020)
  • Table 8. mRNA Treatment Cancer , by Region USD Million (2015-2020)
  • Table 9. mRNA Treatment Tumors , by Region USD Million (2015-2020)
  • Table 10. mRNA Treatment Respiratory Diseases , by Region USD Million (2015-2020)
  • Table 11. mRNA Treatment Other , by Region USD Million (2015-2020)
  • Table 12. mRNA Treatment: by End Use(USD Million)
  • Table 13. mRNA Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 14. mRNA Treatment Specialty Clinics , by Region USD Million (2015-2020)
  • Table 15. mRNA Treatment Surgical Centers , by Region USD Million (2015-2020)
  • Table 16. South America mRNA Treatment, by Country USD Million (2015-2020)
  • Table 17. South America mRNA Treatment, by Type USD Million (2015-2020)
  • Table 18. South America mRNA Treatment, by Application USD Million (2015-2020)
  • Table 19. South America mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 20. Brazil mRNA Treatment, by Type USD Million (2015-2020)
  • Table 21. Brazil mRNA Treatment, by Application USD Million (2015-2020)
  • Table 22. Brazil mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 23. Argentina mRNA Treatment, by Type USD Million (2015-2020)
  • Table 24. Argentina mRNA Treatment, by Application USD Million (2015-2020)
  • Table 25. Argentina mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 26. Rest of South America mRNA Treatment, by Type USD Million (2015-2020)
  • Table 27. Rest of South America mRNA Treatment, by Application USD Million (2015-2020)
  • Table 28. Rest of South America mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 29. Asia Pacific mRNA Treatment, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific mRNA Treatment, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific mRNA Treatment, by Application USD Million (2015-2020)
  • Table 32. Asia Pacific mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 33. China mRNA Treatment, by Type USD Million (2015-2020)
  • Table 34. China mRNA Treatment, by Application USD Million (2015-2020)
  • Table 35. China mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 36. Japan mRNA Treatment, by Type USD Million (2015-2020)
  • Table 37. Japan mRNA Treatment, by Application USD Million (2015-2020)
  • Table 38. Japan mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 39. India mRNA Treatment, by Type USD Million (2015-2020)
  • Table 40. India mRNA Treatment, by Application USD Million (2015-2020)
  • Table 41. India mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 42. South Korea mRNA Treatment, by Type USD Million (2015-2020)
  • Table 43. South Korea mRNA Treatment, by Application USD Million (2015-2020)
  • Table 44. South Korea mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 45. Taiwan mRNA Treatment, by Type USD Million (2015-2020)
  • Table 46. Taiwan mRNA Treatment, by Application USD Million (2015-2020)
  • Table 47. Taiwan mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 48. Australia mRNA Treatment, by Type USD Million (2015-2020)
  • Table 49. Australia mRNA Treatment, by Application USD Million (2015-2020)
  • Table 50. Australia mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific mRNA Treatment, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific mRNA Treatment, by Application USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 54. Europe mRNA Treatment, by Country USD Million (2015-2020)
  • Table 55. Europe mRNA Treatment, by Type USD Million (2015-2020)
  • Table 56. Europe mRNA Treatment, by Application USD Million (2015-2020)
  • Table 57. Europe mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 58. Germany mRNA Treatment, by Type USD Million (2015-2020)
  • Table 59. Germany mRNA Treatment, by Application USD Million (2015-2020)
  • Table 60. Germany mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 61. France mRNA Treatment, by Type USD Million (2015-2020)
  • Table 62. France mRNA Treatment, by Application USD Million (2015-2020)
  • Table 63. France mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 64. Italy mRNA Treatment, by Type USD Million (2015-2020)
  • Table 65. Italy mRNA Treatment, by Application USD Million (2015-2020)
  • Table 66. Italy mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 67. United Kingdom mRNA Treatment, by Type USD Million (2015-2020)
  • Table 68. United Kingdom mRNA Treatment, by Application USD Million (2015-2020)
  • Table 69. United Kingdom mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 70. Netherlands mRNA Treatment, by Type USD Million (2015-2020)
  • Table 71. Netherlands mRNA Treatment, by Application USD Million (2015-2020)
  • Table 72. Netherlands mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 73. Rest of Europe mRNA Treatment, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe mRNA Treatment, by Application USD Million (2015-2020)
  • Table 75. Rest of Europe mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 76. MEA mRNA Treatment, by Country USD Million (2015-2020)
  • Table 77. MEA mRNA Treatment, by Type USD Million (2015-2020)
  • Table 78. MEA mRNA Treatment, by Application USD Million (2015-2020)
  • Table 79. MEA mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 80. Middle East mRNA Treatment, by Type USD Million (2015-2020)
  • Table 81. Middle East mRNA Treatment, by Application USD Million (2015-2020)
  • Table 82. Middle East mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 83. Africa mRNA Treatment, by Type USD Million (2015-2020)
  • Table 84. Africa mRNA Treatment, by Application USD Million (2015-2020)
  • Table 85. Africa mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 86. North America mRNA Treatment, by Country USD Million (2015-2020)
  • Table 87. North America mRNA Treatment, by Type USD Million (2015-2020)
  • Table 88. North America mRNA Treatment, by Application USD Million (2015-2020)
  • Table 89. North America mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 90. United States mRNA Treatment, by Type USD Million (2015-2020)
  • Table 91. United States mRNA Treatment, by Application USD Million (2015-2020)
  • Table 92. United States mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 93. Canada mRNA Treatment, by Type USD Million (2015-2020)
  • Table 94. Canada mRNA Treatment, by Application USD Million (2015-2020)
  • Table 95. Canada mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 96. Mexico mRNA Treatment, by Type USD Million (2015-2020)
  • Table 97. Mexico mRNA Treatment, by Application USD Million (2015-2020)
  • Table 98. Mexico mRNA Treatment, by End Use USD Million (2015-2020)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. mRNA Treatment: by Type(USD Million)
  • Table 110. mRNA Treatment Individualized Cancer Treatment , by Region USD Million (2021-2026)
  • Table 111. mRNA Treatment Infection Prevention , by Region USD Million (2021-2026)
  • Table 112. mRNA Treatment Standardization of Cancer Treatment , by Region USD Million (2021-2026)
  • Table 113. mRNA Treatment Infectious Disease Treatment , by Region USD Million (2021-2026)
  • Table 114. mRNA Treatment: by Application(USD Million)
  • Table 115. mRNA Treatment Infectious Disease , by Region USD Million (2021-2026)
  • Table 116. mRNA Treatment Cancer , by Region USD Million (2021-2026)
  • Table 117. mRNA Treatment Tumors , by Region USD Million (2021-2026)
  • Table 118. mRNA Treatment Respiratory Diseases , by Region USD Million (2021-2026)
  • Table 119. mRNA Treatment Other , by Region USD Million (2021-2026)
  • Table 120. mRNA Treatment: by End Use(USD Million)
  • Table 121. mRNA Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 122. mRNA Treatment Specialty Clinics , by Region USD Million (2021-2026)
  • Table 123. mRNA Treatment Surgical Centers , by Region USD Million (2021-2026)
  • Table 124. South America mRNA Treatment, by Country USD Million (2021-2026)
  • Table 125. South America mRNA Treatment, by Type USD Million (2021-2026)
  • Table 126. South America mRNA Treatment, by Application USD Million (2021-2026)
  • Table 127. South America mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 128. Brazil mRNA Treatment, by Type USD Million (2021-2026)
  • Table 129. Brazil mRNA Treatment, by Application USD Million (2021-2026)
  • Table 130. Brazil mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 131. Argentina mRNA Treatment, by Type USD Million (2021-2026)
  • Table 132. Argentina mRNA Treatment, by Application USD Million (2021-2026)
  • Table 133. Argentina mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 134. Rest of South America mRNA Treatment, by Type USD Million (2021-2026)
  • Table 135. Rest of South America mRNA Treatment, by Application USD Million (2021-2026)
  • Table 136. Rest of South America mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 137. Asia Pacific mRNA Treatment, by Country USD Million (2021-2026)
  • Table 138. Asia Pacific mRNA Treatment, by Type USD Million (2021-2026)
  • Table 139. Asia Pacific mRNA Treatment, by Application USD Million (2021-2026)
  • Table 140. Asia Pacific mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 141. China mRNA Treatment, by Type USD Million (2021-2026)
  • Table 142. China mRNA Treatment, by Application USD Million (2021-2026)
  • Table 143. China mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 144. Japan mRNA Treatment, by Type USD Million (2021-2026)
  • Table 145. Japan mRNA Treatment, by Application USD Million (2021-2026)
  • Table 146. Japan mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 147. India mRNA Treatment, by Type USD Million (2021-2026)
  • Table 148. India mRNA Treatment, by Application USD Million (2021-2026)
  • Table 149. India mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 150. South Korea mRNA Treatment, by Type USD Million (2021-2026)
  • Table 151. South Korea mRNA Treatment, by Application USD Million (2021-2026)
  • Table 152. South Korea mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 153. Taiwan mRNA Treatment, by Type USD Million (2021-2026)
  • Table 154. Taiwan mRNA Treatment, by Application USD Million (2021-2026)
  • Table 155. Taiwan mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 156. Australia mRNA Treatment, by Type USD Million (2021-2026)
  • Table 157. Australia mRNA Treatment, by Application USD Million (2021-2026)
  • Table 158. Australia mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific mRNA Treatment, by Type USD Million (2021-2026)
  • Table 160. Rest of Asia-Pacific mRNA Treatment, by Application USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 162. Europe mRNA Treatment, by Country USD Million (2021-2026)
  • Table 163. Europe mRNA Treatment, by Type USD Million (2021-2026)
  • Table 164. Europe mRNA Treatment, by Application USD Million (2021-2026)
  • Table 165. Europe mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 166. Germany mRNA Treatment, by Type USD Million (2021-2026)
  • Table 167. Germany mRNA Treatment, by Application USD Million (2021-2026)
  • Table 168. Germany mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 169. France mRNA Treatment, by Type USD Million (2021-2026)
  • Table 170. France mRNA Treatment, by Application USD Million (2021-2026)
  • Table 171. France mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 172. Italy mRNA Treatment, by Type USD Million (2021-2026)
  • Table 173. Italy mRNA Treatment, by Application USD Million (2021-2026)
  • Table 174. Italy mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 175. United Kingdom mRNA Treatment, by Type USD Million (2021-2026)
  • Table 176. United Kingdom mRNA Treatment, by Application USD Million (2021-2026)
  • Table 177. United Kingdom mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 178. Netherlands mRNA Treatment, by Type USD Million (2021-2026)
  • Table 179. Netherlands mRNA Treatment, by Application USD Million (2021-2026)
  • Table 180. Netherlands mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 181. Rest of Europe mRNA Treatment, by Type USD Million (2021-2026)
  • Table 182. Rest of Europe mRNA Treatment, by Application USD Million (2021-2026)
  • Table 183. Rest of Europe mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 184. MEA mRNA Treatment, by Country USD Million (2021-2026)
  • Table 185. MEA mRNA Treatment, by Type USD Million (2021-2026)
  • Table 186. MEA mRNA Treatment, by Application USD Million (2021-2026)
  • Table 187. MEA mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 188. Middle East mRNA Treatment, by Type USD Million (2021-2026)
  • Table 189. Middle East mRNA Treatment, by Application USD Million (2021-2026)
  • Table 190. Middle East mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 191. Africa mRNA Treatment, by Type USD Million (2021-2026)
  • Table 192. Africa mRNA Treatment, by Application USD Million (2021-2026)
  • Table 193. Africa mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 194. North America mRNA Treatment, by Country USD Million (2021-2026)
  • Table 195. North America mRNA Treatment, by Type USD Million (2021-2026)
  • Table 196. North America mRNA Treatment, by Application USD Million (2021-2026)
  • Table 197. North America mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 198. United States mRNA Treatment, by Type USD Million (2021-2026)
  • Table 199. United States mRNA Treatment, by Application USD Million (2021-2026)
  • Table 200. United States mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 201. Canada mRNA Treatment, by Type USD Million (2021-2026)
  • Table 202. Canada mRNA Treatment, by Application USD Million (2021-2026)
  • Table 203. Canada mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 204. Mexico mRNA Treatment, by Type USD Million (2021-2026)
  • Table 205. Mexico mRNA Treatment, by Application USD Million (2021-2026)
  • Table 206. Mexico mRNA Treatment, by End Use USD Million (2021-2026)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global mRNA Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global mRNA Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global mRNA Treatment: by End Use USD Million (2015-2020)
  • Figure 7. South America mRNA Treatment Share (%), by Country
  • Figure 8. Asia Pacific mRNA Treatment Share (%), by Country
  • Figure 9. Europe mRNA Treatment Share (%), by Country
  • Figure 10. MEA mRNA Treatment Share (%), by Country
  • Figure 11. North America mRNA Treatment Share (%), by Country
  • Figure 12. Global mRNA Treatment share by Players 2020 (%)
  • Figure 13. Global mRNA Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global mRNA Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Serum Institute (India) Revenue, Net Income and Gross profit
  • Figure 17. Serum Institute (India) Revenue: by Geography 2020
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2020
  • Figure 20. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Arcturus Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Arcturus Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Ethris GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Ethris GmbH (Germany) Revenue: by Geography 2020
  • Figure 26. Moderna Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Moderna Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Translate Bio Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Translate Bio Inc. (United States) Revenue: by Geography 2020
  • Figure 30. BioNTech SE (Germany) Revenue, Net Income and Gross profit
  • Figure 31. BioNTech SE (Germany) Revenue: by Geography 2020
  • Figure 32. CureVac AG (Germany) Revenue, Net Income and Gross profit
  • Figure 33. CureVac AG (Germany) Revenue: by Geography 2020
  • Figure 34. Argos Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Argos Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Global mRNA Treatment: by Type USD Million (2021-2026)
  • Figure 37. Global mRNA Treatment: by Application USD Million (2021-2026)
  • Figure 38. Global mRNA Treatment: by End Use USD Million (2021-2026)
  • Figure 39. South America mRNA Treatment Share (%), by Country
  • Figure 40. Asia Pacific mRNA Treatment Share (%), by Country
  • Figure 41. Europe mRNA Treatment Share (%), by Country
  • Figure 42. MEA mRNA Treatment Share (%), by Country
  • Figure 43. North America mRNA Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Serum Institute (India)
  • Pfizer (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Arcturus Therapeutics Inc. (United States)
  • Ethris GmbH (Germany)
  • Moderna Therapeutics Inc. (United States)
  • Translate Bio Inc. (United States)
  • BioNTech SE (Germany)
  • CureVac AG (Germany)
  • Argos Therapeutics Inc. (United States)
Additional players considered in the study are as follows:
Etherna (Belgium) , Sangamo Therapeutics Inc. (United States) , Merck & Co. (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 235 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global mRNA Treatment Market Quantitative research analysis
Global mRNA Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Serum Institute (India), Pfizer (United States), GlaxoSmithKline PLC (United Kingdom), Arcturus Therapeutics Inc. (United States), Ethris GmbH (Germany), Moderna Therapeutics Inc. (United States), Translate Bio Inc. (United States), BioNTech SE (Germany), CureVac AG (Germany) and Argos Therapeutics Inc. (United States) etc.
Analysts at AMA estimates mRNA Treatment Market to reach USDXXX by 2026.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global mRNA Treatment Market Report?

Have a Query? Click Here

Other Related Reports

In Vitro Fertilization Banking Services Comprehensive Study by Type (Egg Banking, Sperm Banking), End User (Cryobanks, Fertility Clinics, Hospitals, Research Organisations), Form (Fresh, Frozen) Pla...
$ 3500
Dental Prophy Paste Comprehensive Study by Type (With Fluoride, With-out Fluoride), Application (Dental Clinic, Dental Support Organizations, Mid-Size Clinics, Hospitals), Availablity (Sparkle prophy...
$ 3750
Value-Based Healthcare Services Comprehensive Study by Type (Bundled Payment, Capitation Models, Pay for Performance, Patient-Centred Medical Home, Shared Risk, Shared Savings), Application (Provider...
$ 3650
Nanoparticle Mediated Delivery Comprehensive Study by Type (Organic Nanoparticles (A,B), Inorganic Nanoparticles (C–G), Hybrid Nanoparticles), Application (Hospitals, Laboratories, Biopharmaceutical ...
$ 3650
Elective Healthcare Services Comprehensive Study by Type (Medical And Diagnostic Laboratory Services, Dental Services, Ambulatory Health Care Services, Residential Nursing Care Services, Others), App...
$ 3650
Gallbladder Treatment Comprehensive Study by Treatment (Surgical (Immunotherapy, Chemotherapy, Radiation Therapy), Non-Surgical (Medication)), End Use (Hospitals, Gynecology Clinics), Stage (Stage I,...
$ 3650